PI3K/AKT/mTOR pathway inhibitors have emerged as a promising class of targeted therapies for the treatment of cSCC (Jiang et al., 2020[89]; Ye et al., 2023[188]). The gene discussed is AKT1; the disease is skin squamous cell carcinoma.